U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. CDER Small Business & Industry Assistance (SBIA)
  5. Writing the “Indications and Usage” Section of Labeling: FDA’s New Draft Guidance
  1. CDER Small Business & Industry Assistance (SBIA)

Writing the “Indications and Usage” Section of Labeling: FDA’s New Draft Guidance

Thursday, September 27, 2018
1:30 p.m. to 2:30 p.m. EDT

This webinar will provide insight on FDA’s recommendations for the “Indications and Usage” section of labeling as outlined in the draft guidance Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products – Content and Format.  

FDA-approved labeling is the primary communication tool for providing information on the safe and effective use of drugs to the medical community. This draft guidance, when finalized, will assist drug and biological product applicants in developing the “Indications and Usage” section of labeling. This will ulti

mately help health care providers identify appropriate treatment options for their patients.

WHY ATTEND?

Webinar participants will hear directly from the FDA on current recommendations for:

  • How to write, organize, and format the information in the “Indications and Usage” section
  • General principles to consider when drafting the “Indications and Usage” section
  • When to include limitations of use in the “Indications and Usage” section

WHO SHOULD ATTEND?

Industry professionals, including (but not limited to) those working in:

  • Labeling development
  • Medical affairs
  • General regulatory
  • Promotion and advertising
  • Other stakeholders with interests related to prescription drug labeling (e.g., payors)

FDA SPEAKER

Iris P. Masucci, Pharm.D.
Special Assistant for Labeling
Office of Medical Policy
Center for Drug Evaluation and Research

FDA RESOURCES

 
CONTINUING EDUCATION

This event is eligible for up to one credit towards a RAC recertification. Only in-person attendance will qualify for the CE. Attendance certificates are only available for two weeks after the event.

Back to Top